BPC-157 vs SS-31 (Elamipretide) vs TB-500

A three-way comparison to help you find the right peptide for your research goals.

BPC-157

Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.

Full details →

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

TB-500

Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.

Full details →

Side-by-Side Comparison

Aspect	BPC-157	SS-31 (Elamipretide)	TB-500
Dose Range	250 mcg–500 mcg	20 mg–40 mg	2 mg–2.5 mg
Frequency	2x daily	1x daily	Less than daily
Cycle Length	4–6 weeks	4–12 weeks	4–8 weeks
Route	subcutaneous	subcutaneous	subcutaneous
Mechanism	BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels.	Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.	TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing.
Typical Dosage	Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied.	Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.	Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks.
Administration	Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable.	Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.	Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites.
Side Effects	Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses.	Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache.	May cause temporary fatigue, headache, or localized irritation at injection sites.
Best For	Muscle Growth Recovery & Healing	Recovery & Healing Anti-Aging & Longevity	Muscle Growth Recovery & Healing